Polycythemia vera: An appraisal of the biology and management 10 years after the discovery of JAK2 V617F Journal Article

Authors: Stein, B. L.; Oh, S. T.; Berenzon, D.; Hobbs, G. S.; Kremyanskaya, M.; Rampal, R. K.; Abboud, C. N.; Adler, K.; Heaney, M. L.; Jabbour, E. J.; Komrokji, R. S.; Moliterno, A. R.; Ritchie, E. K.; Rice, L.; Mascarenhas, J.; Hoffman, R.
Article Title: Polycythemia vera: An appraisal of the biology and management 10 years after the discovery of JAK2 V617F
Abstract: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A decade after the seminal discovery of an activating mutation in the tyrosine kinase JAK2 in nearly all patients with PV, new treatment options are finally beginning to emerge, necessitating a critical reappraisal of the underlying pathogenesis and therapeutic modalities available for PV. Herein, we comprehensively review clinical aspects of PV including diagnostic considerations, natural history, and risk factors for thrombosis. We summarize recent studies delineating the genetic basis of PV, including their implications for evolution to myelofibrosis and secondary acute myeloid leukemia. We assess the quality of evidence to support the use of currently available therapies, including aspirin, phlebotomy, hydroxyurea, and interferon. We analyze recent studies evaluating the safety and efficacy of JAK inhibitors, such as ruxolitinib, and evaluate their role in the context of other available therapies for PV. This review provides a framework for practicing hematologists and oncologists to make rational treatment decisions for patients with PV. (C) 2015 by American Society of Clinical Oncology
Keywords: tyrosine kinase jak2; essential thrombocythemia; mutations; high-risk; quality-of-life; myeloproliferative neoplasms; leukemic transformation; organization diagnostic-criteria; jak2v617f allele burden; jak2 exon-12; red-cell mass
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 33
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-11-20
Start Page: 3953
End Page: 3960
Language: English
ACCESSION: WOS:000366020600019
DOI: 10.1200/jco.2015.61.6474
PUBMED: 26324368
PMCID: PMC4979103
Notes: Review -- Source: Wos
Altmetric Score
MSK Authors
  1. Raajit Kumar Rampal
    128 Rampal